ArticleNature communications2021
Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment.
Erratum issuedAbstract read
In one paragraph
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 78 papers.
0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed.
- Deciphering resistance mechanisms in cancer: final report of MATCH-R study with a focus on molecular drivers and PDX development.Molecular cancer · 2024Trial
- A Living Multi-Omics PDX Biobank of High-Risk Sarcomas Reveals ecDNA-Driven Oncogene Amplification in Osteosarcoma and Enables Preclinical Precision Oncology.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers.Cancer research · 2026Article
- A platform of serially transplantable AML PDX models covering subgroups for which no cell lines exist.HemaSphere · 2026Article
- The application of experimental models for the drug discovery for digestive tumors.Molecular cancer · 2026Review
- Harnessing PDX and PDX 2.0: the next-generation paradigm for precision oncology and translational breakthroughs.Molecular cancer · 2026Review
- Establishment of a Large-Scale PDX Library of Head and Neck Cancers for Functional Precision Oncology.Cancer medicine · 2026Article
- Ex vivo drug sensitivity profiling to complement molecular profiling in pediatric precision oncology.NPJ precision oncology · 2026Article
- Comprehensive DNA profiling strategy for patient-derived xenograft model authentication in the J-PDX library.Scientific reports · 2025Article
- A Feasibility Study of Co-Established Patient-Derived Subcutaneous Xenograft and Organotypic Slice Cultures in Hormone-Naive Primary Prostate Cancer Preclinical Modeling: A Single-Institution Experience.Life (Basel, Switzerland) · 2025Article
- Advances in the Molecular Biology of Chondrosarcoma for Drug Discovery and Precision Medicine.Cancers · 2025Review
- Acquired resistance in cancer: towards targeted therapeutic strategies.Nature reviews. Cancer · 2025Review
- KDM4C inhibition blocks tumor growth in basal breast cancer by promoting cathepsin L-mediated histone H3 cleavage.Nature genetics · 2025Article
- The Lung Cancer Autochthonous Model Gene Expression Database Enables Cross-Study Comparisons of the Transcriptomic Landscapes Across Mouse Models.Cancer research · 2025Article
- Tumor break load quantitates structural variant-associated genomic instability with biological and clinical relevance across cancers.NPJ precision oncology · 2025Article
- Combination therapy with Chicoric acid and PD-1/PD-L1 blockade improves the immunotherapy response in patient-derived ovarian cancer xenograft model.Cell communication and signaling : CCS · 2025Article
- PDX models for functional precision oncology and discovery science.Nature reviews. Cancer · 2025Review
- Cancer brain metastasis: molecular mechanisms and therapeutic strategies.Molecular biomedicine · 2025Review
- Chondrosarcoma: New Molecular Insights, Challenges in Near-Patient Preclinical Modeling, and Therapeutic Approaches.International journal of molecular sciences · 2025Review
- Review
18 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
50 authors.
Hua Sun *Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA.ORCID http://orcid.org/0000-0003-2169-0808
Song Cao *Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
R Jay Mashl *Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
Chia-Kuei Mo *Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
Simone Zaccaria *Department of Computer Science, Princeton University, Princeton, NJ, USA.ORCID http://orcid.org/0000-0002-5265-7392
Michael C WendlMcDonnell Genome Institute, Washington University in St. Louis, St. Louis, MO, USA.
Sherri R DaviesDepartment of Medicine, Washington University in St. Louis, St. Louis, MO, USA.ORCID http://orcid.org/0000-0002-7141-8354
Matthew H BaileyHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Tina M PrimeauDepartment of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
Jeremy HoogDepartment of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
Jacqueline L MuddDepartment of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
Dennis A DeanSeven Bridges Genomics, Inc., Cambridge, Charlestown, MA, USA.
Rajesh PatidarFrederick National Laboratory for Cancer Research, Frederick, MD, USA.
Li ChenFrederick National Laboratory for Cancer Research, Frederick, MD, USA.
Matthew A WyczalkowskiDepartment of Medicine, Washington University in St. Louis, St. Louis, MO, USA.ORCID http://orcid.org/0000-0003-4197-551X
Reyka G JayasingheDepartment of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
Fernanda Martins RodriguesDepartment of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
Nadezhda V TerekhanovaDepartment of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
Yize LiDepartment of Medicine, Washington University in St. Louis, St. Louis, MO, USA.ORCID http://orcid.org/0000-0003-1074-281X
Kian-Huat LimDepartment of Medicine, Washington University in St. Louis, St. Louis, MO, USA.ORCID http://orcid.org/0000-0002-2766-200X
Andrea Wang-GillamDepartment of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
Brian A Van TineDepartment of Medicine, Washington University in St. Louis, St. Louis, MO, USA.ORCID http://orcid.org/0000-0003-4572-6668
Cynthia X MaDepartment of Medicine, Washington University in St. Louis, St. Louis, MO, USA.ORCID http://orcid.org/0000-0002-8156-7492
Rebecca AftSiteman Cancer Center, Washington University in St. Louis, St. Louis, MO, USA.
Katherine C FuhDepartment of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
Julie K SchwarzSiteman Cancer Center, Washington University in St. Louis, St. Louis, MO, USA.ORCID http://orcid.org/0000-0003-2407-7531
Jose P ZevallosSiteman Cancer Center, Washington University in St. Louis, St. Louis, MO, USA.
Sidharth V PuramSiteman Cancer Center, Washington University in St. Louis, St. Louis, MO, USA.
John F DipersioDepartment of Medicine, Washington University in St. Louis, St. Louis, MO, USA.ORCID http://orcid.org/0000-0002-0429-3133
NCI PDXNet Consortium
Brandi Davis-DusenberySeven Bridges Genomics, Inc., Cambridge, Charlestown, MA, USA.
Matthew J EllisLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA.
Michael T LewisLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA.
Michael A DaviesThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-0977-0912
Meenhard HerlynThe Wistar Institute, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0003-0839-0739
Bingliang FangThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jack A RothThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-8955-1313
Alana L WelmHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.ORCID http://orcid.org/0000-0002-1412-1351
Bryan E WelmHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Funda Meric-BernstamThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-6816-6072
Feng ChenDepartment of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
Ryan C FieldsSiteman Cancer Center, Washington University in St. Louis, St. Louis, MO, USA.
Shunqiang LiDepartment of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
Ramaswamy GovindanDepartment of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
James H DoroshowDivision of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.
Jeffrey A MoscowInvestigational Drug Branch, National Cancer Institute, Bethesda, MD, USA.
Yvonne A EvrardFrederick National Laboratory for Cancer Research, Frederick, MD, USA.ORCID http://orcid.org/0000-0002-3475-4850
Jeffrey H ChuangThe Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.ORCID http://orcid.org/0000-0002-3298-2358
Benjamin J RaphaelDepartment of Computer Science, Princeton University, Princeton, NJ, USA.ORCID http://orcid.org/0000-0003-1274-048X
Li DingDepartment of Medicine, Washington University in St. Louis, St. Louis, MO, USA. lding@wustl.edu.ORCID http://orcid.org/0000-0003-1517-2975
Funding
WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6MTumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI PAUL M. LIEBERMAN · 1985 to 2026
$75.9MTumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Michael M Ittmann · 2007 to 2026
$73.9MUTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI KATHARINE S ULLMAN · 1986 to 2026
$72.6MShared Resource ManagementP30CA034196 · NCI · JACKSON LABORATORY · PI William Carl Skarnes · 1985 to 2026
$61.9MUNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HEYMACH, JOHN V., MINNA, JOHN D. · 1996 to 2024
$57.4MConvalescent Plasma to Limit Coronavirus Associated ComplicationsUL1TR003167 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI KARP, DANIEL D, MCPHERSON, DAVID D · 2019 to 2023
$45.3MResearch Project 2 - Targeting Melanoma Tumor Survival and Apoptotic MachineryU54CA224070 · NCI · WISTAR INSTITUTE · PI Jessie Villanueva · 2017 to 2026
$13.9MTolinapant efficacy in a subset of triple negative breast cancersU54CA224076 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Michael T. Lewis · 2017 to 2026
$13.5MWashington University PDX Development and Trial Center - Evaluation of Abemaciclib in Combination with Olaparib in Ovarian Cancer and Breast Cancer Patient-derived Xenograft ModelsU54CA224083 · NCI · WASHINGTON UNIVERSITY · PI Brian Andrew Van Tine · 2017 to 2026
$13.0MPDXNet Data Commons and Coordinating CenterU24CA224067 · NCI · JACKSON LABORATORY · PI Jeffrey Hsu-Min Chuang · 2017 to 2026
$9.8MUniversity of Texas PDX Development and Trial CenterU54CA224065 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KOPETZ, SCOTT · 2017 to 2022
$7.7MCCR NIH HHS HHSN261200800001CNCATS NIH HHS UL1 TR003167NCI NIH HHS 75N91019D00024NCI NIH HHS HHSN261200800001ENCI NIH HHS HHSN261201400008CNCI NIH HHS HHSN261201500003CNCI NIH HHS HHSN261201500003INCI NIH HHS K08 CA237732NCI NIH HHS P30 CA010815NCI NIH HHS P30 CA034196NCI NIH HHS P30 CA042014NCI NIH HHS P30 CA125123NCI NIH HHS P50 CA070907NCI NIH HHS R50 CA211199NCI NIH HHS U24 CA224067NCI NIH HHS U54 CA224065NCI NIH HHS U54 CA224070NCI NIH HHS U54 CA224076NCI NIH HHS U54 CA224083NCI NIH HHS U54 CA233223NCI NIH HHS U54 CA233306
Abstract
Development of candidate cancer treatments is a resource-intensive process, with the research community continuing to investigate options beyond static genomic characterization. Toward this goal, we have established the genomic landscapes of 536 patient-derived xenograft (PDX) models across 25 cancer types, together with mutation, copy number, fusion, transcriptomic profiles, and NCI-MATCH arms. Compared with human tumors, PDXs typically have higher purity and fit to investigate dynamic driver events and molecular properties via multiple time points from same case PDXs. Here, we report on dynamic genomic landscapes and pharmacogenomic associations, including associations between activating oncogenic events and drugs, correlations between whole-genome duplications and subclone events, and the potential PDX models for NCI-MATCH trials. Lastly, we provide a web portal having comprehensive pan-cancer PDX genomic profiles and source code to facilitate identification of more druggable events and further insights into PDXs' recapitulation of human tumors.
Indexed as
HeterograftsXenograft Model Antitumor AssaysAnimalsDisease Models, AnimalFemaleGene Expression Regulation, NeoplasticGenomeGenomicsHumansMaleMiceModels, BiologicalMutationNeoplasmsTranscriptome
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.